Contribute Try STAT+ Today

Good morning, everyone, and nice to see you again after a long holiday break on this side of the pond. We hope the weekend respite, however long it lasted, was refreshing and reassuring. After all, that oh-so familiar routine of phone calls, Zoom meetings and lengthening to-do lists has returned with a vengeance. Such are the signs of progress, we hope. And so, we are also indulging in yet another part of our routine — the ritual cup of stimulation. Our choice today is maple bourbon. Please feel free to join us. Meanwhile, here are some tidbits. Good luck, today, and do keep in touch. …

A group of nine leading pharmaceutical and biotechnology companies pledged to only seek approval for Covid-19 vaccines demonstrated to be safe and effective, an apparent attempt to provide public reassurance despite the widely held view that the Covid-19 vaccine development process is politically tainted, STAT notes. In a statement, the companies pledged to “make the safety and well-being of vaccinated individuals our top priority.” Last week, the BIO trade group issued an open letter that made the same points.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.